Recombinant Adeno-associated Virus Administration for Patients With Menkes Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

EARLY_PHASE1

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-18

Study Completion Date

2022-11-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is a single-center, open, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of recombinant adeno-associated virus administration for patients with Menkes syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age

NCT04440163

Meningococcal Vaccine

COMPLETED PHASE3

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

NCT04440176

Meningococcal Vaccine

COMPLETED PHASE2

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

NCT02140762

Meningococcal Disease

COMPLETED PHASE2

Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®

NCT00850603

Meningococcal Infections Meningitis

COMPLETED PHASE4

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

NCT01992536

Meningococcal Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Who can participate? Patients with Menkes syndrome were diagnosed by combining clinical and genetic diagnoses.

How to conduct this study? In this study, the constructed recombinant adeno-associated virus preparation will be delivered to patients with Menkes syndrome. After administration, close follow-up will be conducted for at least three months, followed by regular follow-up until at least the 12th month. The efficacy and safety of treatment will be observed and evaluated. After the completion of the study, participants will decide whether to participate in the long-term follow-up program for five years.

What are the possible benefits and risks of participating? Benefits: This study may prolong the life span and improve the prognosis of Menkes syndrome subjects. The information obtained from this study will help determine what treatment may be safe and effective for other subjects with similar conditions.

Risks: Subjects may have adverse reactions to the treatment. These adverse reactions may include abnormal liver injury, fever, thrombocytopenia, thrombotic microangiopathy, and possibly others.

Where is the study run? Kunming Hope of Health Hospital.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menkes Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A single-arm study of recombinant adeno-associated virus

An open, single-arm study of recombinant adeno-associated virus

Group Type EXPERIMENTAL

Recombinant adeno-associated virus administration

Intervention Type DRUG

The investigational medical product will be injected from 1E12 GC/kg to 1E14 GC/kg.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Recombinant adeno-associated virus administration

The investigational medical product will be injected from 1E12 GC/kg to 1E14 GC/kg.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The definitive diagnosis of Menkes disease is determined by molecular genetic confirmation of ATP7A mutations.
2. Disorder of copper metabolism with the serum copper \< 50 ug/dl (reference 70-180 ug/dl) and ceruloplasmin \< 20 mg/dl (reference 20-45 mg/dl) in the absence of copper supplement injection.
3. Clinical onsets of developmental retardation, seizures, and hypotonia with delay in poor head control and inability to sit at the age of 2-3 months.
4. willingness to complete the informed consent process and to comply with study procedures and visit schedule.
5. willingness to agree with the demand of nasal or gastrostomy feeding for nutrition maintenance in the opinion of the investigator.

Exclusion Criteria

1. Inability to be accepted for delivering the Investigational medical product due to failure to recover from severe or acute diseases.
2. Presence of specific anti-AAV antibodies.
3. Active viral infection (includes HIV, COVID-19, or serology positive for hepatitis B or C).
4. Allergy to the substance or excipients in the Investigational medical product solution.
5. Previous or current participation in any other gene therapies.
6. Severe abnormality of hepatic, renal, and cardiac function.

Eligible Sex

ALL

Accepts Healthy Volunteers

No